Loading…
Employees: 125
Size Hansa Biopharma (HNSA.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $410M, the 196th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 39.46 on 6 Nov 2026.
Performance Over six months the shares gained 39.0%, against -16.2% for the median peer and +8.2% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +10.5%); the operating margin is -303.9% (peer median -1.8%).
Valuation It trades at 23.7× enterprise value to sales against a peer median of 5.2× (2nd most expensive of 18).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 189M | SEK 222M | SEK 171M | SEK 134M | SEK 155M |
| Revenue growth | — | +30% | +28% | -13% | — |
| Gross profit | SEK 120M | SEK 128M | SEK 77.7M | SEK 69.3M | SEK 116M |
| EBITDA | n/a | -SEK 484M | -SEK 591M | -SEK 780M | -SEK 556M |
| Net income | -SEK 770M | -SEK 534M | -SEK 807M | -SEK 832M | -SEK 611M |
| Free cash flow | -SEK 536M | -SEK 549M | -SEK 675M | -SEK 756M | -SEK 506M |
| Capital expenditure | SEK 28.5M | SEK 0 | SEK 116,000 | SEK 284,000 | SEK 3.33M |
| Total debt | SEK 1.03B | SEK 939M | SEK 1.08B | SEK 867M | SEK 791M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HNSA.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.2% | -12.4% | 2nd highest of 21 |
| 6-month return | +39.0% | -16.2% | 3rd highest of 20 |
| Distance from 52-week high | -18.2% | -42.2% | 4th highest of 21 |
| Revenue growth (TTM) | -3.6% | +10.5% | 3rd lowest of 18 |
| Operating margin | -303.9% | -1.8% | 2nd lowest of 18 |
| EV / Sales | 23.7× | 5.2× | 2nd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 1.5× | 2.8% | +0.3% |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 2.9× | n/a | n/a |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | 7.0× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |